Everolimus is a mammalian target of rapamycin inhibitor that has been recently approved for the treatment of patients with advanced progressive pancreatic neuroendocrine tumor. Here, we present a case in which an early therapy response to everolimus was effectively demonstrated by Ga-DOTATATE PET/CT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RLU.0000000000001242 | DOI Listing |
Publication Analysis
Top Keywords
response everolimus
8
pancreatic neuroendocrine
8
neuroendocrine tumor
8
early response
4
everolimus therapy
4
therapy detected
4
detected 68ga-dotatate
4
68ga-dotatate pet/ct
4
pet/ct patient
4
patient pancreatic
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!